Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Protalix BioTherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of recombinant therapeutic proteins expressed in plant cell-based systems. The company operates within the biopharmaceutical and rare disease industries, with a primary emphasis on enzyme replacement therapies for genetic disorders. Protalix’s core revenue drivers are derived from partnered commercialization agreements, milestone payments, and royalties related to approved products and late-stage clinical assets.
The company is best known for its proprietary plant cell-based protein expression platform, ProCellEx®, which is designed to enable cost-efficient manufacturing and differentiated glycosylation profiles compared to traditional mammalian cell systems. Protalix was founded in 1993 and initially focused on agricultural biotechnology before pivoting in the early 2000s to human therapeutics. It became a publicly traded company in 2006 and has since evolved into a rare-disease-focused biotech with one FDA-approved product and one commercially launched therapy outside the United States.
Business Operations
Protalix’s operations are centered on the research, development, and manufacturing of biologic drugs using its proprietary plant cell expression technology. Its primary commercial product is taliglucerase alfa (Elelyso®), an enzyme replacement therapy for Gaucher disease, which is manufactured by Protalix and marketed globally through Pfizer Inc. Protalix supplies the active pharmaceutical ingredient and earns revenues through supply agreements and royalties.
The company’s lead growth asset is pegunigalsidase alfa (Elfabrio® / PRX‑102), a long-acting enzyme replacement therapy for Fabry disease, which is co-developed and commercialized through a global collaboration with Chiesi Farmaceutici S.p.A. Protalix retains manufacturing responsibilities and receives milestone payments and tiered royalties. Operations include in-house R&D and GMP manufacturing facilities primarily located in Israel, supporting both clinical development and commercial supply.
Strategic Position & Investments
Protalix’s strategic direction is focused on leveraging its plant cell-based expression platform to develop differentiated biologics for rare and orphan diseases, particularly where improved stability, dosing frequency, or immunogenicity profiles may offer competitive advantages. The commercial launch of Elfabrio® in multiple international markets represents a central growth initiative, with continued regulatory and market expansion supported by its partner Chiesi Farmaceutici S.p.A.
In addition to its Fabry and Gaucher disease programs, Protalix has invested in earlier-stage pipeline candidates targeting inflammatory and metabolic disorders, including PRX‑115 and PRX‑119, though these programs remain preclinical or early clinical. The company has not historically pursued large acquisitions, instead emphasizing strategic partnerships and internal platform-driven development to manage capital efficiency.
Geographic Footprint
Protalix is headquartered in Carmiel, Israel, where it maintains its primary research, development, and manufacturing operations. Its commercial reach is global through partnerships, with approved products marketed in North America, Europe, Latin America, and parts of Asia-Pacific via collaborators.
International influence is primarily achieved through licensing and supply agreements rather than direct sales infrastructure. The company’s collaboration with Pfizer Inc. supports market access in the United States and other regions for Gaucher disease, while its alliance with Chiesi Farmaceutici S.p.A. enables broad international commercialization of Fabry disease therapy across Europe and additional global markets.
Leadership & Governance
Protalix is led by an executive team with experience in biotechnology development, regulatory strategy, and global pharmaceutical partnerships. Governance emphasizes disciplined capital allocation, late-stage asset monetization, and platform validation through commercial success. The leadership’s stated strategic vision centers on transforming plant-based expression into a clinically and commercially proven alternative for biologic drug development.
Key executives include:
- Dror Bashan – President and Chief Executive Officer
- Eyal Rubin – Chief Financial Officer
- Dr. Alon Aharon – Senior Vice President, Research and Development
- Gadi Oron – Vice President, Operations
- Yoseph Shaaltiel – Co-Founder and Member of the Board of Directors